{"count": 32, "results": [{"_id": "33514420", "pmid": 33514420, "pmcid": "PMC7845128", "title": "Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis", "journal": "Diabetol Metab Syndr", "authors": ["Qi YY", "Yan L", "Wang ZM", "Wang X", "Meng H", "Li WB", "Chen DC", "Li M", "Liu J", "An ST"], "date": "2021-01-29T00:00:00Z", "doi": "10.1186/s13098-021-00626-7", "meta_date_publication": "2021 Jan 29", "meta_volume": "13", "meta_issue": "1", "meta_pages": "15", "score": 50277.953, "text_hl": "...@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ had a clear advantage in reducing the risk of @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@MACE@@@ in the entire @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@HTG@@@ population analyzed in this meta-analysis. ", "citations": {"NLM": "Qi YY, Yan L, Wang ZM, Wang X, Meng H, Li WB, Chen DC, Li M, Liu J, An ST. Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis Diabetol Metab Syndr. 2021 Jan 29;13(1):15. PMID: 33514420", "BibTeX": "@article{33514420, title={Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis}, author={Qi YY and Yan L and Wang ZM and Wang X and Meng H and Li WB and Chen DC and Li M and Liu J and An ST}, journal={Diabetol Metab Syndr}, volume={13}, number={1}, pages={15}}"}}, {"_id": "36960628", "pmid": 36960628, "pmcid": "PMC10372610", "title": "A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer", "journal": "Cancer Res Treat", "authors": ["Lee Y", "Lee SH", "Lee GK", "Lim EJ", "Han JY"], "date": "2023-03-20T00:00:00Z", "doi": "10.4143/crt.2023.283", "meta_date_publication": "2023 Mar 20", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50256.28, "text_hl": "...5. @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@Hypertriglyceridemia@@@ and survival", "citations": {"NLM": "Lee Y, Lee SH, Lee GK, Lim EJ, Han JY. A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer Cancer Res Treat. 2023 Mar 20;():. PMID: 36960628", "BibTeX": "@article{36960628, title={A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer}, author={Lee Y and Lee SH and Lee GK and Lim EJ and Han JY}, journal={Cancer Res Treat}}"}}, {"_id": "34907765", "pmid": 34907765, "title": "The effects of Rosmarinus officinalis L. essential oil and its nanoemulsion on dyslipidemic Wistar rats.", "journal": "J Appl Biomed", "authors": ["Santos Rodrigues AP", "Faria E Souza BS", "Alves Barros AS", "de Oliveira Carvalho H", "Lobato Duarte J", "Leticia Elizandra Boettger M", "Barbosa R", "Maciel Ferreira A", "Maciel Ferreira I", "Fernandes CP", "Cesar Matias Pereira A", "Tavares Carvalho JC"], "date": "2020-12-01T00:00:00Z", "doi": "10.32725/jab.2020.016", "meta_date_publication": "2020 Dec", "meta_volume": "18", "meta_issue": "4", "meta_pages": "126-135", "score": 50249.15, "text_hl": "Similar results were observed on the positive control treated with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@. @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@Dyslipidemia@@@ induced with coconut saturated-fat (CSF) caused @DISEASE_Abdominal_Injuries @DISEASE_MESH:D000007 @@@abdominal fat@@@ gain, @DISEASE_Hypercholesterolemia @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@, @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@, increased LDL levels, and @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherogenesis@@@ in the aorta. ", "citations": {"NLM": "Santos Rodrigues AP, Faria E Souza BS, Alves Barros AS, de Oliveira Carvalho H, Lobato Duarte J, Leticia Elizandra Boettger M, Barbosa R, Maciel Ferreira A, Maciel Ferreira I, Fernandes CP, Cesar Matias Pereira A, Tavares Carvalho JC. The effects of Rosmarinus officinalis L. essential oil and its nanoemulsion on dyslipidemic Wistar rats. J Appl Biomed. 2020 Dec;18(4):126-135. PMID: 34907765", "BibTeX": "@article{34907765, title={The effects of Rosmarinus officinalis L. essential oil and its nanoemulsion on dyslipidemic Wistar rats.}, author={Santos Rodrigues AP and Faria E Souza BS and Alves Barros AS and de Oliveira Carvalho H and Lobato Duarte J and Leticia Elizandra Boettger M and Barbosa R and Maciel Ferreira A and Maciel Ferreira I and Fernandes CP and Cesar Matias Pereira A and Tavares Carvalho JC}, journal={J Appl Biomed}, volume={18}, number={4}, pages={126-135}}"}}, {"_id": "40718116", "pmid": 40718116, "title": "Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.", "journal": "Ther Clin Risk Manag", "authors": ["Deng T", "Yan L", "Li J", "Liu G", "Yin A", "Feng Y", "Zheng M", "Zhang C", "Huang H", "Huang Q", "Lin A", "Jiang J", "Kong B", "Liu J"], "date": "2025-07-21T00:00:00Z", "doi": "10.2147/TCRM.S526755", "meta_date_publication": "2025", "meta_volume": "21", "meta_issue": "", "meta_pages": "1135-1147", "score": 50238.016, "text_hl": "@DISEASE_Hypertension @DISEASE_MESH:D006973 @@@Hypertension@@@ and cardiovascular events were mostly managed by early interventions using beta-blockers. @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@Hypertriglyceridemia@@@ was mostly managed using @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@. ", "citations": {"NLM": "Deng T, Yan L, Li J, Liu G, Yin A, Feng Y, Zheng M, Zhang C, Huang H, Huang Q, Lin A, Jiang J, Kong B, Liu J. Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study. Ther Clin Risk Manag. 2025;21():1135-1147. PMID: 40718116", "BibTeX": "@article{40718116, title={Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.}, author={Deng T and Yan L and Li J and Liu G and Yin A and Feng Y and Zheng M and Zhang C and Huang H and Huang Q and Lin A and Jiang J and Kong B and Liu J}, journal={Ther Clin Risk Manag}, volume={21}, pages={1135-1147}}"}}, {"_id": "24080592", "pmid": 24080592, "title": "Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia.", "journal": "Pharmacology", "authors": ["Krysiak R", "Okopien B"], "date": "2013-01-01T00:00:00Z", "doi": "10.1159/000341909", "meta_date_publication": "2013", "meta_volume": "92", "meta_issue": "3-4", "meta_pages": "187-90", "score": 50087.562, "text_hl": "Effect of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ on hemostasis in @SPECIES_9606 @@@patients@@@ with isolated @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@.", "citations": {"NLM": "Krysiak R, Okopien B. Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia. Pharmacology. 2013;92(3-4):187-90. PMID: 24080592", "BibTeX": "@article{24080592, title={Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia.}, author={Krysiak R and Okopien B}, journal={Pharmacology}, volume={92}, number={3-4}, pages={187-90}}"}}, {"_id": "23159435", "pmid": 23159435, "title": "Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia.", "journal": "Eur J Intern Med", "authors": ["Krysiak R", "Okopien B"], "date": "2013-04-01T00:00:00Z", "doi": "10.1016/j.ejim.2012.10.010", "meta_date_publication": "2013 Apr", "meta_volume": "24", "meta_issue": "3", "meta_pages": "255-9", "score": 50084.8, "text_hl": "Monocyte-suppressing effects of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in @SPECIES_9606 @@@patients@@@ with isolated @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@.", "citations": {"NLM": "Krysiak R, Okopien B. Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia. Eur J Intern Med. 2013 Apr;24(3):255-9. PMID: 23159435", "BibTeX": "@article{23159435, title={Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia.}, author={Krysiak R and Okopien B}, journal={Eur J Intern Med}, volume={24}, number={3}, pages={255-9}}"}}, {"_id": "23950601", "pmid": 23950601, "title": "Lymphocyte-suppressing action of simvastatin in patients with isolated hypertriglyceridemia.", "journal": "Pharmacol Rep", "authors": ["Krysiak R", "Okopień B"], "date": "2013-01-01T00:00:00Z", "doi": "10.1016/s1734-1140(13)71056-9", "meta_date_publication": "2013", "meta_volume": "65", "meta_issue": "3", "meta_pages": "756-60", "score": 50084.566, "text_hl": "Lymphocyte-suppressing action of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in @SPECIES_9606 @@@patients@@@ with isolated @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@.", "citations": {"NLM": "Krysiak R, Okopień B. Lymphocyte-suppressing action of simvastatin in patients with isolated hypertriglyceridemia. Pharmacol Rep. 2013;65(3):756-60. PMID: 23950601", "BibTeX": "@article{23950601, title={Lymphocyte-suppressing action of simvastatin in patients with isolated hypertriglyceridemia.}, author={Krysiak R and Okopień B}, journal={Pharmacol Rep}, volume={65}, number={3}, pages={756-60}}"}}, {"_id": "12539808", "pmid": 12539808, "title": "Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.", "journal": "Clin Cardiol", "authors": ["Isaacsohn J", "Hunninghake D", "Schrott H", "Dujovne CA", "Knopp R", "Weiss SR", "Bays H", "Crouse JR 3rd", "Davidson MH", "Keilson LM", "McKenney J", "Korenman SG", "Dobs AS", "Stein E", "Krauss RM", "Maccubbin D", "Cho M", "Plotkin DJ", "Mitchel YB"], "date": "2003-01-01T00:00:00Z", "doi": "10.1002/clc.4960260105", "meta_date_publication": "2003 Jan", "meta_volume": "26", "meta_issue": "1", "meta_pages": "18-24", "score": 50077.18, "text_hl": "Effects of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, an @GENE_HMGCR @GENE_3156 @@@HMG-CoA reductase@@@ inhibitor, in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@.", "citations": {"NLM": "Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR 3rd, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan;26(1):18-24. PMID: 12539808", "BibTeX": "@article{12539808, title={Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.}, author={Isaacsohn J and Hunninghake D and Schrott H and Dujovne CA and Knopp R and Weiss SR and Bays H and Crouse JR 3rd and Davidson MH and Keilson LM and McKenney J and Korenman SG and Dobs AS and Stein E and Krauss RM and Maccubbin D and Cho M and Plotkin DJ and Mitchel YB}, journal={Clin Cardiol}, volume={26}, number={1}, pages={18-24}}"}}, {"_id": "10656170", "pmid": 10656170, "title": "Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.", "journal": "Nutr Metab Cardiovasc Dis", "authors": ["Vigna GB", "Donega P", "Passaro A", "Zanca R", "Cattin L", "Fonda M", "Pauciullo P", "Marotta G", "Fellin R", "Gasparrini S", "Piliego T"], "date": "1999-10-01T00:00:00Z", "meta_date_publication": "1999 Oct", "meta_volume": "9", "meta_issue": "5", "meta_pages": "234-43", "score": 50069.94, "text_hl": "Post-prandial effects of @CHEMICAL_Gemfibrozil @CHEMICAL_MESH:D015248 @@@gemfibrozil@@@ vs @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in @DISEASE_Hyperlipoproteinemia_Type_II @DISEASE_MESH:D006938 @@@hypercholesterolemic@@@ subjects with borderline @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@.", "citations": {"NLM": "Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. Nutr Metab Cardiovasc Dis. 1999 Oct;9(5):234-43. PMID: 10656170", "BibTeX": "@article{10656170, title={Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.}, author={Vigna GB and Donega P and Passaro A and Zanca R and Cattin L and Fonda M and Pauciullo P and Marotta G and Fellin R and Gasparrini S and Piliego T}, journal={Nutr Metab Cardiovasc Dis}, volume={9}, number={5}, pages={234-43}}"}}, {"_id": "30587933", "pmid": 30587933, "pmcid": "PMC6304249", "title": "Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects", "journal": "Drug Des Devel Ther", "authors": ["Li G", "Zhao M", "Qiu F", "Sun Y", "Zhao L"], "date": "2018-12-20T00:00:00Z", "doi": "10.2147/DDDT.S185487", "meta_date_publication": "2019", "meta_volume": "13", "meta_issue": "", "meta_pages": "129-139", "score": 50068.93, "text_hl": "@CHEMICAL_Fenofibrate @CHEMICAL_MESH:D011345 @@@Fenofibrate@@@ (@CHEMICAL_Fenofibrate @CHEMICAL_MESH:D011345 @@@Fbt@@@) is a prodrug that has been used to reduce low-density-lipoprotein cholesterol, @CHEMICAL_Triglycerides @CHEMICAL_MESH:D014280 @@@triglycerides@@@, and increase high-density-lipoprotein cholesterol. @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ (@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Svt@@@) is a classic @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@-lowering drug that is widely used in the treatment of @DISEASE_Hypercholesterolemia @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@ and @<m>DISEASE_Hypertriglyceridemia</m> @DISEASE_MESH:D015228 @@@hypertriglyceridemia@@@, while berberine chloride (Bbr) is a novel hypolipidemic agent and its blood-@CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@-reducing mechanism is distinct from traditional drugs. ", "citations": {"NLM": "Li G, Zhao M, Qiu F, Sun Y, Zhao L. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects Drug Des Devel Ther. 2019;13():129-139. PMID: 30587933", "BibTeX": "@article{30587933, title={Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects}, author={Li G and Zhao M and Qiu F and Sun Y and Zhao L}, journal={Drug Des Devel Ther}, volume={13}, pages={129-139}}"}}]}